LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 1 | J19 | 72 | hr | 1401 | 1037 | 4223 | 0.2456 | -0.1292 |
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 2 | J19 | 72 | hr | 1401 | 1112 | 4223 | 0.2633 | -0.1026 |
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 3 | J19 | 72 | hr | 1401 | 1137 | 4223 | 0.2692 | -0.0938 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 1 | M07 | 72 | hr | 1401 | 1239 | 4223 | 0.2934 | -0.0576 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 2 | M07 | 72 | hr | 1401 | 1173 | 4223 | 0.2778 | -0.0810 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 3 | M07 | 72 | hr | 1401 | 1101 | 4223 | 0.2607 | -0.1065 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 1 | P13 | 72 | hr | 1401 | 3610 | 4223 | 0.8548 | 0.7827 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 2 | P13 | 72 | hr | 1401 | 4123 | 4223 | 0.9763 | 0.9645 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 3 | P13 | 72 | hr | 1401 | 4417 | 4223 | 1.0459 | 1.0687 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 1 | H01 | 72 | hr | 1401 | 986 | 4223 | 0.2335 | -0.1473 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 2 | H01 | 72 | hr | 1401 | 922 | 4223 | 0.2183 | -0.1700 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 3 | H01 | 72 | hr | 1401 | 1027 | 4223 | 0.2432 | -0.1327 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 1 | L19 | 72 | hr | 1401 | 1359 | 4223 | 0.3218 | -0.0151 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 2 | L19 | 72 | hr | 1401 | 1449 | 4223 | 0.3431 | 0.0168 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 3 | L19 | 72 | hr | 1401 | 1406 | 4223 | 0.3329 | 0.0016 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 1 | H07 | 72 | hr | 1401 | 1000 | 4223 | 0.2368 | -0.1423 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 2 | H07 | 72 | hr | 1401 | 1052 | 4223 | 0.2491 | -0.1239 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 3 | H07 | 72 | hr | 1401 | 1230 | 4223 | 0.2913 | -0.0608 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 1 | G07 | 72 | hr | 1401 | 1211 | 4223 | 0.2868 | -0.0675 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 2 | G07 | 72 | hr | 1401 | 1088 | 4223 | 0.2576 | -0.1111 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 3 | G07 | 72 | hr | 1401 | 1079 | 4223 | 0.2555 | -0.1143 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 1 | F01 | 72 | hr | 1401 | 1104 | 4223 | 0.2614 | -0.1055 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 2 | F01 | 72 | hr | 1401 | 894 | 4223 | 0.2117 | -0.1799 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 3 | F01 | 72 | hr | 1401 | 1191 | 4223 | 0.2820 | -0.0746 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 1 | G01 | 72 | hr | 1401 | 578 | 4223 | 0.1369 | -0.2919 |